Product image of Olmedipin Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide) supplied by GNH India

Olmedipin Plus

Active Ingredient:
Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide
Origin:
EU

Olmedipin Plus (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, the active ingredient in Olmedipin Plus, is a combination antihypertensive presented as a tablet for oral use. It treats high blood pressure in adults, often when single‑agent therapy is insufficient.

GNH India supplies Olmedipin Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Olmedipin Plus is a combination antihypertensive that addresses several pathways involved in blood pressure regulation.

  • Hypertension: helps achieve target blood pressure when monotherapy is inadequate.
  • Resistant hypertension: provides additional control through three complementary mechanisms.
  • Hypertensive patients with edema risk: amlodipine’s vasodilatory effect is balanced by the diuretic component.

How It Works

  • Olmedipin Plus combines three agents that act on distinct aspects of blood pressure control: olmesartan medoxomil blocks the angiotensin II type‑1 receptor, preventing vasoconstriction; amlodipine inhibits calcium influx into vascular smooth‑muscle cells, producing arterial dilation; and hydrochlorothiazide promotes renal sodium and water excretion, reducing plasma volume. The synergistic effect lowers systemic vascular resistance and cardiac output.

Side Effects

Adverse reactions may vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate discomfort.
  • Dizziness or light‑headedness: especially after the first doses.
  • Peripheral edema: swelling of ankles or feet.
  • Fatigue: general feeling of tiredness.
  • Increased urination: due to the diuretic component.
  • Electrolyte imbalance: mild changes in potassium or sodium levels.

Serious or Rare Side Effects

  • Severe hypotension: marked drop in blood pressure causing fainting.
  • Acute kidney injury: sudden decline in renal function.
  • Hyperkalemia: elevated potassium that may affect heart rhythm.
  • Angio‑edema: swelling of lips, tongue or airway.
  • Liver enzyme elevation: abnormal liver function tests.
  • Blood dyscrasias: rare blood cell abnormalities.

Precautions & Warnings

When prescribing Olmedipin Plus, clinicians should evaluate patient history and monitor relevant parameters.

  • Renal impairment: adjust therapy and monitor creatinine.
  • Hepatic disease: use with caution and observe liver function.
  • Electrolyte disturbances: check potassium and sodium levels regularly.
  • Pregnancy: avoid use; teratogenic risk is associated with angiotensin‑II blockers.
  • Concomitant diuretics: assess for additive electrolyte loss.
  • Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Avoid Interactions

Olmedipin Plus may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid)

  • Aliskiren: combined use with angiotensin‑II receptor blockers can increase risk of renal impairment.
  • Potassium‑rich supplements or potassium‑sparing diuretics: may cause dangerous hyper‑kalemia.
  • NSAIDs (high‑dose): can blunt antihypertensive effect and worsen renal function.

Moderate Interactions (Monitor Closely)

  • Lithium: may increase serum lithium levels.
  • CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine concentrations.
  • Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment.

Frequently Asked Questions

Olmedipin Plus is a fixed‑dose combination of olmesartan medoxomil, amlodipine and hydrochlorothiazide used to lower high blood pressure in adults, particularly when single‑agent therapy does not achieve target levels or when resistant hypertension is present.

Olmesartan medoxomil blocks the angiotensin II type‑1 receptor, preventing angiotensin II‑mediated vasoconstriction and aldosterone release. This results in relaxed blood vessels and reduced fluid retention, contributing to lower systemic blood pressure.

The specific dose of Olmedipin Plus is determined by the prescribing clinician based on the patient’s blood pressure, response to therapy and any comorbid conditions. Dosage adjustments are made according to clinical guidelines and individual needs.

Olmesartan medoxomil, a component of Olmedipin Plus, is classified as contraindicated in pregnancy because it can cause fetal toxicity. Use during breastfeeding is not recommended unless the benefits outweigh potential risks, and it should be discussed with a healthcare professional.

To order Olmedipin Plus, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Olmedipin Plus combines an angiotensin‑II receptor blocker, a calcium‑channel blocker and a thiazide diuretic, offering three complementary mechanisms in a single tablet. This can simplify regimens and improve adherence compared with taking separate agents, while providing broader blood‑pressure control than monotherapy.

Olmedipin Plus tablets should be stored at ambient temperature, below 25 °C, in their original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Olmedipin Plus is taken orally, usually once daily, with or without food, as directed by a healthcare professional. Swallow the tablet whole with a full glass of water and follow the prescriber’s instructions regarding timing and any dose adjustments.

Serious risks include severe hypotension, acute kidney injury, hyper‑kalemia, angio‑edema and rare blood‑cell disorders. Patients should be monitored for signs such as fainting, rapid weight gain, swelling of the face or lips, and abnormal laboratory results, and seek medical attention promptly if they occur.

Olmedipin Plus should be avoided in patients with known hypersensitivity to any component, in pregnant women, and in individuals with severe renal or hepatic impairment unless specifically advised by a physician. Caution is also warranted for those taking potassium‑rich supplements or certain interacting medications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT